Supernus Stock Slides as Qelbree Sales are Questioned: Examining the Positives and Negatives
Supernus Stock Slides as Qelbree Sales are Questioned: Examining the Positives and Negatives Description: Supernus Pharmaceuticals’ stock has risen 15% since my last “strong buy” rating, despite recent analyst downgrades due to Qelbree’s slowing growth. Supernus’ diverse neuroscience portfolio includes key drugs like Qelbree for ADHD and GOCOVRI for Parkinson’s, with Qelbree’s revenues being potentially…